Venlafaxine. Pharmacology and therapeutic potential in the treatment of depression

Human Psychopharmacology

Volumn 13, Issue 3, 1998, Pages 153-162

  Burnett, Frances E ^a   Dinan, Timothy G ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Adrenergic receptor; Depression; Serotonin noradrenaline reuptake inhibitor; Venlafaxine

Indexed keywords

DESIPRAMINE; DESVENLAFAXINE; DOSULEPIN; DRUG METABOLITE; FLUOXETINE; IMIPRAMINE; N DESMETHYLVENLAFAXINE; N,O DIDESMETHYLVENLAFAXINE; NORADRENALIN UPTAKE INHIBITOR; NORFLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; UNCLASSIFIED DRUG; VENLAFAXINE;

ASTHENIA; CLINICAL TRIAL; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG MECHANISM; DRUG POTENCY; FATIGUE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; NAUSEA; NERVOUSNESS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; SWEATING; VERTIGO; XEROSTOMIA;

EID: 0031966205     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1077(199804)13:3<153::AID-HUP973>3.0.CO;2-S     Document Type: Review

References (72)

1. Amchin, J. D. and Zarycranski, W. M. (1996). Effect of venlafaxine on the pharmacokinetics of alprazolam [abstract]. 36th Annual Meeting of the New Clinical Evaluation Unit of the National Institute of Mental Health, Boca Raton, Florida, May 30.
2. Amchin, J. D., Ereshefsky, L. and Zarycranski, W. M. (1996). Effect of venlafaxine versus fluoxetine on the metabolism of dextromorphan, a CYP2D6 marker [abstract]. Annual Meeting of the American Psychiatric Association, New York, May 7.
3. Anderson, I. M. and Tomenson, B. M. (1994). The efficacy of selective serotonin reuptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. Journal of Psychopharmacology, 8, 238-249.
4. Ball, S. E., Ahern, D., Kao, J. and Scatina, J. (1996). Venlafaxine effects on CYP2D6 dependent imipramine and desipramine 2-hydroxylation; comparative studies with fluoxetine and effects on CYP1A2, CYP3A4 and CYP2C9 [abstract]. Clinical Pharmacology and Therapeutics, 59, 170.
5. Baron, B. M., Ogden, A.-M., Siegel, B. W., Stegeman, J., Ursillo, R. C. and Dudley, M. W. (1988). Rapid down regulation of β-adreneroreceptors by co-administration of desipramine and fluoxetine. European Journal of Pharmacology, 154, 125-134.
6. Benkert, O., Grunder, G., Wetzel, H. and Hackett, D. (1996). A randomised double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. Journal of Psychiatric Research, 30, 441-451.
7. Blanchard, C., Hackett, D., Danjou, P. and Nichols, T. (1995). A randomised double blind comparison of venlafaxine, imipramine and placebo in general practice patients with mild moderate depression. European Neuropsychopharmacology, 5, 308.
8. Bolden-Watson, C. and Richelson, E. (1993). Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sciences, 52, 1023-1029.
9. Brunello, N., Barbaccia, M. L., Chuang, D. M. and Costa, E. (1982). Down regulation of β-adrenergic receptors following repeated injections of desmethylimipramine: permissive role of serotonergic axons. Neuropharmacology, 21, 1145-1149.
10. Clerc, G. E., Ruimy, P. and Verdeau-Pailles, J. (1994). A double blind comparison of fluoxetine in patients hospitalised for major depression. International Clinical Psychopharmacology, 9, 139-143.
11. Crewe, H. K., Lennard, M. S., Tucker, G. T., Woods, F. R. and Haddock, R. (1992). The effect of selective serotonin reuptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. British Journal of Clinical Pharmacology, 34, 262-265.
12. Cusack, B., Nelson, A. and Richelson, E. (1994). Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology, 114, 559-565.
13. Danish University Antidepressant Group (1986). Citalopram: clinical effect profile in comparison with clomipramine; a controlled multicenter study. Psychopharmacology, 90, 131-138.
14. Danish University Antidepressant Group (1990). Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Journal of Affective Disorders, 18, 289-299.
15. Danjou, P. and Hackett, D. (1995). Safety and tolerance profile of venlafaxine. International Clinical Psychopharmacology, 10 (suppl. 2), 15-20.
16. Davidson, J. (1989). Seizures and bupropion, a review. Journal of Clinical Psychiatry, 50, 256-261.
17. Derivan, A. and Rudolph, R. (1988). Fixed dose placebo-controlled study of venlafaxine in depressed patients. Psychopharmacology, 96, 144.
18. DeVane, C. L. (1992). Pharmacokinetics of the selective serotonin reuptake inhibitors. Journal of Clinical Psychiatry, 53 (suppl.), 13-20.
19. Dierick, M., Ravizza, L., Realini, R. and Martin, A. (1996). A double blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Progress in Neuropsychopharmacology and Biological Psychiatry, 20, 57-71.
20. Entsuah, R., Rudolph, R., Derivan, R. and Rickels, K. (1993). A low relapse rate confirms the long term efficacy of venlafaxine in the treatment of major depression [abstract]. 32nd Annual Meeting of the American College of Neuropsychopharmacology, Honolulu, Hawaii, Dec. 11-17, p. 192.
21. Ereshefsky, L. (1996). Drug-drug interactions involving antidepressants: focus on venlafaxine. Journal of Clinical Psychopharmacology, 16 (suppl. 2), 37-50.
22. Fabre, L. F. and Putman, H. P. 3rd (1987). An ascending single dose tolerance study of Wy, 45,030, a bicyclic antidepressant in healthy men. Current Therapeutic Research, 42, 901-909.
23. Farah, A., Colenda, C. and Winston-Salem, N. C. (1995). Combination ECT and antidepressant therapy (letter). American Journal of Geriatric Psychiatry, 3, 356-357.
24. Guelfi, J. D., White, C., Hackett, D., Guichoux, J. Y. and Magni, G. (1995). Effectiveness of venlafaxine in patients hospitalised with major depression and melancholia. Journal of Clinical Psychiatry, 56, 450-458.
25. Haskins, J. T., Moyer, J. A., Muth, E. A. and Sigg, E. B. (1985). DMI, WY-45,030, WY-45-881 and ciramadol inhibit locus coeruleus neuronal activity. European Journal of Pharmacology, 115, 139-146.
26. 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man. Xenbiotica, 23, 349-359.
27. Hyttel, J., Overdo, K. F. and Arnt, J. (1984). Biochemical effects and drug levels in rats after long term treatment with the specific 5HT reuptake inhibitor, citalopram. Psychopharmacology, 83, 20-27.
28. Janowsky, A., Okada, F., Manier, C. L., Applegate, C. D., Sulser, F. and Steranka, L. R. (1982). Role of serotonergic input in the regulation of the β-adrenoreceptor coupled adenylate-cyclase system. Science, 218, 900-901.
29. Khan, A., Fabre, L. and Rudolph, R. (1991). Venlafaxine in depressed outpatients. Psychopharmacology Bulletin, 27, 141-144.
30. Klamerus, K. J., Maloney, K., Rudolph, R. L., Sisenwine, S. F., Jusko, W. J. and Chiang, S. T. (1992). Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. Journal of Clinical Pharmacology, 32, 716-724.
31. Lam, Y. W. F., Ereshefsky, L., Riesenman, C. and Simpson, J. (1996). In vivo comparison of CYP2D6 inhibition among SSRIs: implications for drug interactions. Presented at the 1996 Annual Meeting of the American Psychiatric Association, May 7, New York.
32. 3H-imipramine binding in rat hypothalamus: association with serotonin but not noradrenaline by antidepressant drugs and their derivatives. Science, 210, 1133-1135.
33. Lecable, P., Letzelter, J.-M., Lichtblau, E., Prak, H., De Ruiter, F., Bruers, Y. and Hackett, D. (1995). An open label study of the clinical acceptability of venlafaxine for depression. Primary Care Psychiatry, 1, 119-126.
34. Lecrubier, Y., Moon, C., Shifano, F., Blanchard, C., Danjou, P. and Hackett, D. (in press). Double blind, randomised, placebo-controlled comparison of venlafaxine and imipramine in general practice patients with mild to moderate depression. Acta Psychiatrica Scandinavica.
35. Lloyd, G. K., Cronin, S., Fletcher, A. and Mitchell, P. J. (1992). The profile of venlafaxine, a novel antidepressant agent, in behavioural antidepressant models. Clinical Neuropharmacology, 15 (suppl. 1B), 428.
36. Lydiard, R. B., Pottash, A. L. C. and Gold, M. S. (1984). Speed of onset of action of the newer antidepressants. Psychopharmacology Bulletin, 20 (suppl. 2), 258-271.
37. Manier, D. H., Gillespie, D. D., Sterenka, L. R. and Sulser, F. (1984). A pivotal role for serotonin (5HT) in the regulation of beta adrenoreceptors by antidepressants: reversibility of an action of parachlorophenylalanine by 5 hydroxytrptophan. Experientia, 40, 1223.
38. Manji, H. and Brown, J. H. (1987). The antidepressant effect of β-adrenoreceptor subsensitivity: a brief review and clinical implications. Canadian Journal of Psychiatry, 32, 788-797.
39. Mendels, J., Johnston, R., Mattes, J. and Riesenberg, R. (1993). Efficacy and safety of b.i.d. doses of venlafaxine in a dose response study. Psychopharmacology Bulletin, 29, 169-174.
40. Mitchell, P. J. and Fletcher, A. (1992). Venlafaxine exhibits an antidepressant like profile of activity on the social and agonistic behaviour of rats. Clinical Neuropharmacology, 15 (suppl. 1B), 428.
41. Morton, W. A., Sonne, S. C. and Verga, M. A. (1995). Venlafaxine: a structurally unique and novel antidepressant. The Annals of Pharmacotherapy, 29, 387-395.
42. Moyer, J. A., Muth, E. A., Haskins, J. T., Lappe, R. W. and Sigg, E. B. (1984). In vivo antidepressant profiles of the novel bicyclic compounds Wy-45,030, and Wy-45,881 [abstract]. Society for Neuroscience, 10, 261.
43. Muth, E. A., Moyer, J. A., Haskins, J. T., Andree, T. H. and Morris Husbands, G. E. (1991). Biochemical, neurophysiological, and behavioural effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Development Research, 23, 191-199.
44. Muth, E. A., Haskins, J. T., Moyer, J. A., Husbands, G. E., Nielsen, S. E. and Sigg, E. B. (1986). Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochemical Pharmacology, 35, 4493-4497.
45. Nelson, D. R., Pratt, G. D., Palmer, K. J., Johnson, A. M. and Bowery, N. G. (1991). Effect of paroxetine, a selective 5-hydroxytryptamine uptake inhibitor, on β-adrenoreceptors in rat brain: autoradiographic and functional studies. Neuropharmacology, 30, 607-616.
46. Nelson, J. C., Mazure, C. M., Bowers, N. E. B. and Jatlow, P. I. (1991). A preliminary open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Archives of General Psychiatry, 48, 303-307.
47. Nierenberg, A., Feigner, J. P. and Rudolph, R. (1994). Venlafaxine for treatment resistant unipolar depression. Journal of Clinical Psychopharmacology, 14, 419-423.
48. Otton, S. V., Ball, S. E., Cheung, S. W., Inaba, T., Rudolph, R. and Sellers, E. M. (1996). Venlafaxine oxidation in vitro is catalysed by CYP2D6. British Journal of Clinical Pharmacology, 41, 149-156.
49. Parker, V., Troy, S. and Rudolph, R. (1991). The potential pharmacokinetic interaction between venlafaxine and lithium carbonate. Journal of Clinical Pharmacology, 31, 867.
50. Parker, V., Paerg, L., Maloney, K., Rudolph, R., Derivan, A. and Chiang, S. (1990). The effect of ageing and sex on the pharmacokinetics of venlafaxine. Journal of Clinical Pharmacology, 30, 832.
51. Pollock, B. G., Perel, J. M., Kupfer, D. J., Bowler, K. A. and Miewald, J. M. (1993). Early response patterns associated with successful clomipramine treatment. Journal of Clinical Psychopharmacology, 13, 442-447.
52. 3H-imipramine binding. European Journal of Pharmacology, 61, 373-380.
53. Rudolph, R., Feighner, J. and Rickels, K. (in press). A double blind, randomised, placebo-controlled trial of venlafaxine in outpatients with major depression. Journal of Clinical Psychiatry.
54. Roose, S. P., Glassman, A. H., Attia, E. and Woodring, S. (1994). Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. American Journal of Psychiatry, 151, 1735-1739.
55. Saletu, B., Grunberger, J., Andererm, P., Linzmayer, L., Semlitsch, H. V. and Magni, G. (1992). Pharmacodynamics of venlafaxine evaluated by EEG brain mapping, psychometry and psychophysiology. British Journal of Clinical Pharmacology, 33, 589-601.
56. Samuelian, J. C., Tatossian, A. and Hackett, D. (1992). A randomised, double-blind, parallel-group comparison of venlafaxine and clomipramine in out-patients with major depression. Clinical Neuropharmacology, 15 (Suppl. 1B), 324.
57. Schweizer, E., Feigner, J., Mandos, L. A. and Rickels, K. (1994). Comparison of venlafaxine and imipramine in the acute treatment of major depression in out-patients. Journal of Clinical Psychiatry, 55, 104-108.
58. Schweizer, E., Weise, C., Clary, C., Fox, I. and Rickels, K. (1991). Placebo controlled trial of venlafaxine for the treatment of major depression. Journal of Clinical Psychopharmacology, 11, 233-236.
59. Sellers, E. M., Ball, S. E., Cheung, S. W., Inaba, T. and Otton, S. V. (1993). Inhibition by venlafaxine (VF) and other 5HT reuptake inhibitors of the polymorphic enzyme CYP2D6 [abstract]. 22nd Annual Meeting of the American College of Neuropsychopharmacology, Honolulu, Dec. 13-17, p. 163.
60. Semilitsch, H. V., Anderer, P., Saletu, B., Binder, G. A. and Decker, K. A. (1993). Acute effects of the novel antidepressant venlafaxine on cognitive event related potentials (P300), eye blink rate and mood in young healthy subjects. International Clinical Psychopharmacology, 8, 155-166.
61. Shrivastava, R., Cohn, C., Crowder, J., Davidson, J., Dunner, D., Feighner, J. and Patrick, R. (1994). Long term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. Journal of Clinical Psychopharmacology, 14, 322-329.
62. Sulser, F. (1982). Mode of action of antidepressant drugs. Journal of Clinical Psychiatry, 44, 239-332.
63. Troy, S., Bulow, L. and Wallace, D. W. Pharmacokinetic and statistical evaluation of the effect of hepatic disease on the disposition of venlafaxine: final report. Wyeth Ayerst (Philadelphia) data on file.
64. Troy, S., Pierges, A. and Lucki, I. (1992). Venlafaxine pharmacokinetics and pharmacodynamics. Clinical Neuropharmacology, 15 (suppl. 1B), 324.
65. Troy, S., Schultz, R. W. and Parker, V. D. (1994). The effect of renal disease on the disposition of venlafaxine. Clinical Pharmacology and Therapeutics, 56, 14-21.
66. Troy, S., Parker, V., Fruncillo, R. and Chiang, S. T. (1995). The pharmacokinetics of venlafaxine when given in a twice daily regime. Journal of Clinical Pharmacology, 35, 404-409.
67. Tylee, A., Beumont, G., Bowden, M. and Reynolds, A. (1997). A double blind, randomised, 12 week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe major depression in general practice. Primary Care Psychiatry, 3, 51-58.
68. Vetulani, J. and Sulser, F. (1975). Actions of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP generating system in limbic forebrain. Nature, 257, 495.
69. Wang, C. P., Howell, S. R., Scatina, J. and Sisenwine, S. F. (1992). The disposition of venlafaxine enantomers in dogs, rats, and humans receiving venlafaxine. Chirality, 4, 84-90.
70. Westermeyer, J. (1991). Fluoxetine induced tricyclic toxicity: extent and duration. Journal of Clinical Pharmacology, 31, 388-392.
71. Wiklander, B., Danjou, P., Rolan, P., Tamin, S. K. and Toon, S. (1995). Evaluation of the potential pharmakokinetic interaction between venlafaxine and carbamazepine [abstract]. European Neuropsychopharmacology, 5, 310-311.
72. Yardley, J. P., Husbands, G. E. M., Stack, G., Butch, J., Bicksler, J., Moyer, J. A., Muth, E. A., Andree, T., Fletcher, H., James, M. N. G. and Sielecki, A. (1990). 2-Phenyl-2-(1-hydroxycycloalkyl) ethylamine derivatives: synthesis and antidepressant activity. Journal of Medical Chemistry, 33, 2899-2905.